title: TNF is here to stay!
authors.affiliation: Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK.
authors.forename: F
authors.initials: F
authors.lastname: Balkwill
authors.forename: B
authors.initials: B
authors.lastname: Foxwell
authors.forename: F
authors.initials: F
authors.lastname: Brennan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology; D000068800:Etanercept; D010505:Familial Mediterranean Fever / Q000209:etiology; D006609:High Mobility Group Proteins / Q000502:physiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy; D015398:Signal Transduction; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D006609:High Mobility Group Proteins; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept